EPH receptor A5 | Type XIII RTKs: Ephrin receptor family | IUPHAR/BPS Guide to PHARMACOLOGY

Top ▲

EPH receptor A5

Target not currently curated in GtoImmuPdb

Target id: 1825

Nomenclature: EPH receptor A5

Abbreviated Name: EphA5

Family: Type XIII RTKs: Ephrin receptor family

Gene and Protein Information
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 1 1037 4q13.1 EPHA5 EPH receptor A5
Mouse 1 876 5 Epha5 Eph receptor A5
Rat 1 1039 14p21 Epha5 EPH receptor A5
Previous and Unofficial Names
EPH homology kinase 1 | ephrin type-A receptor 5 | tyrosine-protein kinase receptor EHK-1 | bsk | Brain-specific kinase | CEK7 | EHK1 | TYRO4
Database Links
ChEMBL Target
Ensembl Gene
Entrez Gene
Human Protein Atlas
KEGG Enzyme
RefSeq Nucleotide
RefSeq Protein
Selected 3D Structures
Image of receptor 3D structure from RCSB PDB
Description:  Kinase domain of human ephrin type-A receptor 5 (EphA5)
PDB Id:  2R2P
Resolution:  2.4Å
Species:  Human
Enzyme Reaction
EC Number:

Download all structure-activity data for this target as a CSV file

Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
compound 66 [PMID: 19788238] Hs Inhibition 8.5 pIC50 6
pIC50 8.5 (IC50 3x10-9 M) [6]
RIPK3 inhibitor 18 Hs Inhibition 7.8 pIC50 4
pIC50 7.8 (IC50 1.4x10-8 M) [4]
compound 20 [PMID: 23489211] Rn Inhibition 5.6 pIC50 5
pIC50 5.6 (IC50 2.4x10-6 M) [5]
View species-specific inhibitor tables
DiscoveRx KINOMEscan® screen
A screen of 72 inhibitors against 456 human kinases. Quantitative data were derived using DiscoveRx KINOMEscan® platform.
Reference: 2,7

Key to terms and symbols Click column headers to sort
Target used in screen: EPHA5
Ligand Sp. Type Action Value Parameter
dasatinib Hs Inhibitor Inhibition 9.6 pKd
foretinib Hs Inhibitor Inhibition 8.2 pKd
PD-173955 Hs Inhibitor Inhibition 7.8 pKd
bosutinib Hs Inhibitor Inhibition 7.6 pKd
staurosporine Hs Inhibitor Inhibition 7.0 pKd
AST-487 Hs Inhibitor Inhibition 6.8 pKd
vandetanib Hs Inhibitor Inhibition 6.6 pKd
erlotinib Hs Inhibitor Inhibition 6.2 pKd
tamatinib Hs Inhibitor Inhibition 6.1 pKd
crizotinib Hs Inhibitor Inhibition 6.0 pKd
Displaying the top 10 most potent ligands  View all ligands in screen »
EMD Millipore KinaseProfilerTM screen/Reaction Biology Kinase HotspotSM screen
A screen profiling 158 kinase inhibitors (Calbiochem Protein Kinase Inhibitor Library I and II, catalogue numbers 539744 and 539745) for their inhibitory activity at 1µM and 10µM against 234 human recombinant kinases using the EMD Millipore KinaseProfilerTM service.

A screen profiling the inhibitory activity of 178 commercially available kinase inhibitors at 0.5µM against a panel of 300 recombinant protein kinases using the Reaction Biology Corporation Kinase HotspotSM platform.


Reference: 1,3

Key to terms and symbols Click column headers to sort
Target used in screen: EphA5/EPHA5
Ligand Sp. Type Action % Activity remaining at 0.5µM % Activity remaining at 1µM % Activity remaining at 10µM
dasatinib Hs Inhibitor Inhibition 0.2
staurosporine Hs Inhibitor Inhibition 9.3 8.0 1.5
nilotinib Hs Inhibitor Inhibition 22.6
bosutinib Hs Inhibitor Inhibition 37.1
TWS119 Hs Inhibitor Inhibition 41.7 24.0 2.0
PP1 analog II Hs Inhibitor Inhibition 43.5 21.0 5.0
vandetanib Hs Inhibitor Inhibition 54.4
Cdk1/2 inhibitor III Hs Inhibitor Inhibition 56.7 59.0 11.0
aminopurvalanol A Hs Inhibitor Inhibition 64.0 86.0 23.0
dorsomorphin Hs Inhibitor Inhibition 66.4 89.0 37.0
Displaying the top 10 most potent ligands  View all ligands in screen »


Show »

1. Anastassiadis T, Deacon SW, Devarajan K, Ma H, Peterson JR. (2011) Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat. Biotechnol., 29 (11): 1039-45. [PMID:22037377]

2. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK, Zarrinkar PP. (2011) Comprehensive analysis of kinase inhibitor selectivity. Nat. Biotechnol., 29 (11): 1046-51. [PMID:22037378]

3. Gao Y, Davies SP, Augustin M, Woodward A, Patel UA, Kovelman R, Harvey KJ. (2013) A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. Biochem. J., 451 (2): 313-28. [PMID:23398362]

4. Hart AC, Abell L, Guo J, Mertzman ME, Padmanabha R, Macor JE, Chaudhry C, Lu H, O'Malley K, Shaw PJ et al.. (2019) Identification of RIPK3 Type II Inhibitors Using High-Throughput Mechanistic Studies in Hit Triage. ACS Med Chem Lett, Article ASAP. DOI: 10.1021/acsmedchemlett.9b00065

5. Incerti M, Tognolini M, Russo S, Pala D, Giorgio C, Hassan-Mohamed I, Noberini R, Pasquale EB, Vicini P, Piersanti S et al.. (2013) Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. J. Med. Chem., 56 (7): 2936-47. [PMID:23489211]

6. Lafleur K, Huang D, Zhou T, Caflisch A, Nevado C. (2009) Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4). J. Med. Chem., 52 (20): 6433-46. [PMID:19788238]

7. Wodicka LM, Ciceri P, Davis MI, Hunt JP, Floyd M, Salerno S, Hua XH, Ford JM, Armstrong RC, Zarrinkar PP et al.. (2010) Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry. Chem. Biol., 17 (11): 1241-9. [PMID:21095574]

How to cite this page

Type XIII RTKs: Ephrin receptor family: EPH receptor A5. Last modified on 17/05/2019. Accessed on 28/09/2020. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1825.